Literature DB >> 7683157

Inhibition of human immunodeficiency virus type 1 (HIV-1) penetration into target cells by synthetic peptides mimicking the N-terminus of the HIV-1 transmembrane glycoprotein.

V A Slepushkin1, G V Kornilaeva, S M Andreev, M V Sidorova, A O Petrukhina, G R Matsevich, S V Raduk, V B Grigoriev, T V Makarova, V V Lukashov.   

Abstract

To investigate the mechanism of action of the 22-amino-acid HIV fusion peptide on HIV infection, we studied its influence on virus adsorption and HIV-induced syncytium formation. The effect of the peptide preparations on the synthesis of viral antigens in HIV-infected cell cultures was determined by antigen capture assay, and the inhibition of proviral DNA synthesis was detected by hybridization with a HIV-specific oligonucleotide probe after PCR amplification. Fusion peptides inhibited HIV-induced syncytium formation and antigen production in lytic infected cells, and this effect was increased in conjugation with bovine serum albumin or with synthetic net-charged polymer by its C-terminus. The association of peptide with carrier by N-terminus, or with positive-charged polymer or gelatin completely abolished its effect on HIV infection. No peptide preparations influenced HIV-1 chronically infected cells. Because peptide preparations blocked the HIV-specific DNA synthesis 2 hr after infection without influencing virus adsorption and reverse transcription, we concluded that the block of infection occurred during the penetration of virions through the cell membrane. On the basis of results obtained we propose that our peptide preparations could be used for anti-HIV chemotherapy. The possibility of the existence of receptors for gp41 N-terminal region on target cell membrane is discussed.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7683157     DOI: 10.1006/viro.1993.1260

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  8 in total

1.  Ultrastructural characterization of peptide-induced membrane fusion and peptide self-assembly in the lipid bilayer.

Authors:  A S Ulrich; W Tichelaar; G Förster; O Zschörnig; S Weinkauf; H W Meyer
Journal:  Biophys J       Date:  1999-08       Impact factor: 4.033

2.  The coronavirus spike protein is a class I virus fusion protein: structural and functional characterization of the fusion core complex.

Authors:  Berend Jan Bosch; Ruurd van der Zee; Cornelis A M de Haan; Peter J M Rottier
Journal:  J Virol       Date:  2003-08       Impact factor: 5.103

3.  Increase in soluble CD4 binding to and CD4-induced dissociation of gp120 from virions correlates with infectivity of human immunodeficiency virus type 1.

Authors:  R L Willey; M A Martin; K W Peden
Journal:  J Virol       Date:  1994-02       Impact factor: 5.103

4.  Requirement of N-terminal amino acid residues of gp41 for human immunodeficiency virus type 1-mediated cell fusion.

Authors:  H Schaal; M Klein; P Gehrmann; O Adams; A Scheid
Journal:  J Virol       Date:  1995-06       Impact factor: 5.103

Review 5.  Peptide-based Fusion Inhibitors for Preventing the Six-helix Bundle Formation of Class I Fusion Proteins: HIV and Beyond.

Authors:  Ajit Monteiro; Karl O A Yu; Mark D Hicar
Journal:  Curr HIV Res       Date:  2021       Impact factor: 1.341

6.  A synthetic peptide corresponding to a conserved heptad repeat domain is a potent inhibitor of Sendai virus-cell fusion: an emerging similarity with functional domains of other viruses.

Authors:  D Rapaport; M Ovadia; Y Shai
Journal:  EMBO J       Date:  1995-11-15       Impact factor: 11.598

Review 7.  The three lives of viral fusion peptides.

Authors:  Beatriz Apellániz; Nerea Huarte; Eneko Largo; José L Nieva
Journal:  Chem Phys Lipids       Date:  2014-04-02       Impact factor: 3.329

Review 8.  Interfacial pre-transmembrane domains in viral proteins promoting membrane fusion and fission.

Authors:  Maier Lorizate; Nerea Huarte; Asier Sáez-Cirión; José L Nieva
Journal:  Biochim Biophys Acta       Date:  2008-01-03
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.